By For patients with diabetes subsequently diagnosed and hospitalized with COVID-19, use of a sodium-glucose cotransporter-2 inhibitor (SGLT-2i) before COVID-19 infection is associated with lower COVID-19-related adverse outcomes, according to a systematic review and network meta-analysis published online Dec. 6 in JAMA Network Open.
SGLT-2i use before COVID-19 may reduce adverse outcomes in diabetes patients
Close up of chemical microscope and medical research equipment in scientific laboratory. Liquid examination tool with glass lens and blood samples in vacutainers on professional desk
Comments